Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Market Access Five Takeaways from JP Morgan Week 2026 JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.
Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
